Diabetes
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, and basal insulin from our alliance partner Eli Lilly and Company, we are also focused on cardiometabolic indications with a high unmet medical need.
Latest Article on Diabetes

Living a long and healthy life

The Adventures of Reggie the Red Blood Cell

The Future of Diabetes
Related Press Releases

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
Links
Heart Talks
Heart Failure Matters
Downloads
Diabetic Retinopathy
Harold and Dorothy Patient Discussion Factsheet
Type 2 Diabetes
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (accessed Jan 2019)